Mechanisms and Pharmacology of Neuropathic Pain in Multiple Sclerosis.
Behavioral Neurobiology of Chronic Pain
Current topics in behavioral neurosciences, March 2014
Iannitti T, Kerr BJ, Taylor BK, T. Iannitti, B. J. Kerr, B. K. Taylor, Iannitti, T., Kerr, B. J., Taylor, B. K.
Bradley K. Taylor, David P. Finn
The neuropathic pain of multiple sclerosis is quite prevalent and severely impacts quality of life. A few randomized, placebo-controlled, blinded clinical trials suggest that cannabis- and anticonvulsant-based treatments provide partial pain relief, but at the expense of adverse events. An even smaller, but emerging, number of translational studies are using rodent models of experimental autoimmune encephalomyelitis (EAE), which exhibit pain-like behaviors resembling those of Multiple sclerosis (MS) patients. These studies not only support the possible effectiveness of anticonvulsants, but also compel further clinical trials with serotonin-norepinephrine reuptake inhibitors, the immunosuppressant drug rapamycin, or drugs which interfere with glutamatergic neurotransmission. Future behavioral studies in EAE models are essential toward a new pharmacotherapy of multiple sclerosis pain.
|Science communicators (journalists, bloggers, editors)||1||50%|
|Members of the public||1||50%|
|Readers by professional status||Count||As %|
|Student > Master||11||18%|
|Student > Bachelor||10||16%|
|Student > Ph. D. Student||7||11%|
|Student > Postgraduate||6||10%|
|Readers by discipline||Count||As %|
|Medicine and Dentistry||22||35%|
|Agricultural and Biological Sciences||6||10%|
|Pharmacology, Toxicology and Pharmaceutical Science||4||6%|